A landmark study in this area was the UK Protective Diabetes Study (UKPDS) [11], which randomized 1704 overweight (> 120% ideal body weight) patients with newly diagnosed T2DM to receive conventional treatment with diet alone in one trial arm or either metformin, sulphonylurea, or insulin in the other. The gene discussed is INS; the disease is type 2 diabetes mellitus.